CLNN nears NDA submission for ALS nanotherapeutic
CLNN says an ALS nanotherapeutic is nearing NDA submission after clinical survival and neurofilament light benefits, with a strong safety profile. Regulatory review is expected to begin soon, with commercialization targeted next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.